Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Association of Carboxylesterase 1 Gene (CES1) Polymorphism with Weight loss in Children with Attention Deficit Hyperactivity Disorder during Methylphenidate Treatment

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Harvard

APA

CBE

MLA

Vancouver

Author

Bibtex

@article{73725a5eca7645048babeaa5ea376eab,
title = "Association of Carboxylesterase 1 Gene (CES1) Polymorphism with Weight loss in Children with Attention Deficit Hyperactivity Disorder during Methylphenidate Treatment",
abstract = "Children with Attention Deficit Hyperactivity Disorder (ADHD) show large variations in response to methylphenidate (MPH) treatment, which may result from genetic factors associated with MPH metabolism. We aimed at investigating a possible link between the -75 T>G polymorphism in the 5{\textquoteright} untranslated region of the gene coding for carboxylesterase 1 (CES1) and a common adverse effect, weight loss, during the first three months of MPH treatment. We analyzed the association between a CES1 polymorphism and longitudinal clinical data based on retrospective analysis of medical records, from first to last recorded visit at the clinic. By use of poly chain reaction and the Sanger method we genotyped the -75 T>G gene polymorphism and examined the association to clinical response, which was based on retrospective analysis of longitudinal clinical data from medical records. The primary clinical outcome measure was weight loss during the first 3 months of MPH treatment. Data from 74 MPH treated children with ADHD, mean age 8.6 years, 57% males, were analysed. There were n=26 G-carriers (heterozygote TG and homozygote GG) and n=48 TT-homozygotes. The proportion of weight loss and mean weight change differed significantly in G-carriers (88% / -0.279 kg) compared with TT-homozygotes (31% / +0.157 kg). This study shows an association between the -75 T>G polymorphism in CES1 and MPH treatment response, demonstrated by a significantly higher frequency and extent of weight loss in G-carriers compared to TT-homozygotes.",
author = "Maria Oxenb{\o}ll and Kristine Kaalund-Brok and Simone Rasmussen and Ditte Bjerre and Gesche J{\"u}rgens and Hansen, {Ebba Holme} and Plessen, {Kerstin J} and Rasmussen, {Henrik Berg} and Pagsberg, {Anne Katrine} and {The INDICES Consortium} and Dalhoff, {Kim Peder} and Claus Stage and Tine Houmann and Pia Jeppesen and Kristine Kaalund-Brok and Hansen, {Peter Riis} and Kristensen, {Karl Emil} and Pagsberg, {Anne Katrine} and Plessen, {Kerstin J} and Rasmussen, {Henrik Berg} and Ditte Bjerre and Madsen, {Majbritt Busk} and Laura Ferrero and Kristian Linnet and Ragnar Thomsen and Werge, {Thomas Mears} and J{\o}rgen Dyrborg and {Glenn Lauritsen}, Maj-Britt",
year = "2017",
month = mar,
day = "21",
language = "English",
volume = "2",
pages = "1--8",
journal = "SM Journal of Bioinformatics and Proteomics",
number = "1",

}

RIS

TY - JOUR

T1 - Association of Carboxylesterase 1 Gene (CES1) Polymorphism with Weight loss in Children with Attention Deficit Hyperactivity Disorder during Methylphenidate Treatment

AU - Oxenbøll, Maria

AU - Kaalund-Brok, Kristine

AU - Rasmussen, Simone

AU - Bjerre, Ditte

AU - Jürgens, Gesche

AU - Hansen, Ebba Holme

AU - Plessen , Kerstin J

AU - Rasmussen, Henrik Berg

AU - Pagsberg, Anne Katrine

AU - The INDICES Consortium

A2 - Dalhoff, Kim Peder

A2 - Stage, Claus

A2 - Houmann, Tine

A2 - Jeppesen, Pia

A2 - Kaalund-Brok, Kristine

A2 - Hansen, Peter Riis

A2 - Kristensen, Karl Emil

A2 - Pagsberg, Anne Katrine

A2 - Plessen , Kerstin J

A2 - Rasmussen, Henrik Berg

A2 - Bjerre, Ditte

A2 - Madsen, Majbritt Busk

A2 - Ferrero, Laura

A2 - Linnet, Kristian

A2 - Thomsen, Ragnar

A2 - Werge, Thomas Mears

A2 - Dyrborg, Jørgen

A2 - Glenn Lauritsen, Maj-Britt

PY - 2017/3/21

Y1 - 2017/3/21

N2 - Children with Attention Deficit Hyperactivity Disorder (ADHD) show large variations in response to methylphenidate (MPH) treatment, which may result from genetic factors associated with MPH metabolism. We aimed at investigating a possible link between the -75 T>G polymorphism in the 5’ untranslated region of the gene coding for carboxylesterase 1 (CES1) and a common adverse effect, weight loss, during the first three months of MPH treatment. We analyzed the association between a CES1 polymorphism and longitudinal clinical data based on retrospective analysis of medical records, from first to last recorded visit at the clinic. By use of poly chain reaction and the Sanger method we genotyped the -75 T>G gene polymorphism and examined the association to clinical response, which was based on retrospective analysis of longitudinal clinical data from medical records. The primary clinical outcome measure was weight loss during the first 3 months of MPH treatment. Data from 74 MPH treated children with ADHD, mean age 8.6 years, 57% males, were analysed. There were n=26 G-carriers (heterozygote TG and homozygote GG) and n=48 TT-homozygotes. The proportion of weight loss and mean weight change differed significantly in G-carriers (88% / -0.279 kg) compared with TT-homozygotes (31% / +0.157 kg). This study shows an association between the -75 T>G polymorphism in CES1 and MPH treatment response, demonstrated by a significantly higher frequency and extent of weight loss in G-carriers compared to TT-homozygotes.

AB - Children with Attention Deficit Hyperactivity Disorder (ADHD) show large variations in response to methylphenidate (MPH) treatment, which may result from genetic factors associated with MPH metabolism. We aimed at investigating a possible link between the -75 T>G polymorphism in the 5’ untranslated region of the gene coding for carboxylesterase 1 (CES1) and a common adverse effect, weight loss, during the first three months of MPH treatment. We analyzed the association between a CES1 polymorphism and longitudinal clinical data based on retrospective analysis of medical records, from first to last recorded visit at the clinic. By use of poly chain reaction and the Sanger method we genotyped the -75 T>G gene polymorphism and examined the association to clinical response, which was based on retrospective analysis of longitudinal clinical data from medical records. The primary clinical outcome measure was weight loss during the first 3 months of MPH treatment. Data from 74 MPH treated children with ADHD, mean age 8.6 years, 57% males, were analysed. There were n=26 G-carriers (heterozygote TG and homozygote GG) and n=48 TT-homozygotes. The proportion of weight loss and mean weight change differed significantly in G-carriers (88% / -0.279 kg) compared with TT-homozygotes (31% / +0.157 kg). This study shows an association between the -75 T>G polymorphism in CES1 and MPH treatment response, demonstrated by a significantly higher frequency and extent of weight loss in G-carriers compared to TT-homozygotes.

UR - http://smjournals.com/bioinformatics-proteomics/in-press.php

M3 - Journal article

VL - 2

SP - 1

EP - 8

JO - SM Journal of Bioinformatics and Proteomics

JF - SM Journal of Bioinformatics and Proteomics

IS - 1

M1 - 1010

ER -

ID: 51534290